Vertex Pharmaceuticals stock has surged to a new all-time high, gaining around 17% this year and outpacing the S&P 500's roughly 10% return. The company's recent quarterly sales rose 8% to about $3 billion, but investors are betting on future growth from its gene therapy Casgevy and non-opioid pain drug Journavx, along with a robust pipeline of clinical trials. However, the stock now trades at about 31 times trailing earnings, well above the S&P 500 average of 25, and its price-to-earnings-growth ratio of around 2.0 suggests much of that anticipated growth may already be priced in. While the business has strong long-term potential, the elevated valuation could limit further upside and increase downside risk.
Vertex Pharmaceuticals IncStock hits all-time high and has strong pipeline, but valuation concerns (high P/E and PEG ratio) could limit upside.